Citius Oncology reports 78% QoQ increase in new institutions ordering LYMPHIR; vials up 31%

CITIUS ONCOLOGY, INC.

New institutional accounts ordering LYMPHIR increased 78% QoQ; total institutions now 42.
Vials ordered by institutions rose 31% during quarter ended June 30, 2026.
LYMPHIR has near-universal payer coverage; initial CTCL market exceeds $400M.
Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
Wholesaler orders have begun to reflect increased demand; revenue recognized on wholesale orders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.